UPPSALA, Sweden, March 22, 2018 /PRNewswire/ -- Orexo's Annual Report for the 2017 fiscal year has been published and canbe downloaded on the company's website, www.orexo.com (investors/reports, presentations and audiocasts). This year, a Sustainability Report is included in the Annual Report.
For further information, please contact:Orexo AB (publ.)
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product ZubsolvŪ. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.
This information is information that Orexo AB (publ.) is obliged to make public in accordance with the Securities Market Act. The information was submitted for publication at 8.00 am CET on March 22, 2018.
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/orexo-publishes-the-annual-report-for-2017-300618058.html
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All